The World In A Grain Of Sand: CG Oncology The World In A Grain Of Sand podcast

Contenuto fornito da KdT Ventures. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da KdT Ventures o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

The World In A Grain Of Sand »
The World in a Grain of Sand: CG Oncology

5M ago 43:43

M4A•Pagina principale dell'episodio

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss CG Oncology, the first biotech IPO of 2024. We dive into:

The various subtypes of bladder cancer, and one of the most unique standard of care treatment paradigms in oncology, which utilizes a live attenuated virus to treat the disease
Supply chain and manufacturing issues that have limited access to SoC therapy in bladder cancer
CG Oncology’s lead (and only) asset, an oncolytic immunotherapy which has delivered impressive complete response data in bladder cancer
Challenges and open questions around complex manufacturing, clinical and commercial adoption, and competition for CG’s lead asset
Bull vs bear case for CG Oncology

For updates from KdT, ⁠⁠subscribe to our Substack⁠⁠.

13 episodi

#Trading #Business #KdT Ventures